Ryman Healthcare Limited (ASX:RYM): Retirement Village Sales, Aged Care Occupancy and FY27 Developments

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Ryman Healthcare Limited (ASX:RYM): Retirement Village Sales, Aged Care Occupancy and FY27 Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ryman Healthcare (ASX:RYM) recorded 379 occupation right agreement sales in Q2 FY27.
Q2 FY27 resale volumes rose 14% year on year, reaching 312 agreements.
FY26 operating revenue increased 10% to NZD 849.1 million.
FY26 free cash flow reached NZD 188.3 million, compared with an outflow in FY25.

Ryman Healthcare Limited (ASX:RYM) operates integrated retirement villages and aged care communities across New Zealand and Australia, offering independent living, assisted living and residential care. On 22 October 2026, Ryman Healthcare (ASX:RYM) was quoted at AUD 1.485, up 0.68% in the reported trading session. Its latest operating disclosure covers the September 2026 quarter, including retirement unit sales, care occupancy and new capacity, following the company’s FY26 financial results.

Company Business

Ryman develops, owns and operates retirement villages that combine accommodation and services with access to higher levels of care as residents’ needs change. Its retirement living offering includes independent units and serviced apartments; its aged care operations provide residential care across its New Zealand and Australian footprint. The company’s investor information identifies operations spanning both countries, with Victoria forming its principal Australian presence.

Its retirement living sales are primarily recorded through occupation right agreements, or ORAs. Resales of existing units and sales of newly completed accommodation are reported separately. Fees from care and villages, deferred management fees and capital arrangements all influence financial performance. For Ryman Healthcare (ASX:RYM), the relationship between occupancy, the housing market and available village stock remains central to operating activity.

Recent Development

In October 2026, Ryman reported 379 ORA sales for Q2 FY27, comprising 312 resales and 67 new sales. Resale volumes increased 14% compared with the equivalent quarter a year earlier, while net resale contracts rose 11%. The company said serviced apartments contributed to resale activity and highlighted the early take-up of its Ryman Select product at participating villages.

Unoccupied new retirement living inventory declined by 67 units during the quarter to 347 units. The October opening of the main building at Richard Hadlee Village in Christchurch added 77 retirement living units and 65 care beds. Ryman Healthcare (ASX:RYM) reiterated its FY27 construction guidance of 157–168 retirement living units and aged care beds combined.

Total aged care occupancy reached 94.0% in Q2 FY27, increasing 3.3 percentage points year on year. Mature aged care centre occupancy was 95.4%, compared with 95.7% a year earlier. The five mature Victorian care centres recorded occupancy of 97.9%, versus 96.1% in the corresponding period.

Financial Performance and Sector Context

For the year ended 31 March 2026, Ryman reported operating revenue of NZD 849.1 million, up 10% from NZD 771.1 million. Care and village fees increased from NZD 570.9 million to NZD 639.9 million. Operating EBITDAF, a company-defined measure excluding fair value movements, rose from NZD 45.5 million to NZD 88.3 million. Despite that improvement, the company reported a statutory net loss after tax of NZD 171.3 million, compared with a NZD 513.7 million loss in FY25.

FY26 free cash flow was positive NZD 188.3 million, compared with negative NZD 94.2 million in FY25. Capital expenditure was NZD 221.8 million, down from NZD 535.9 million. The company reported gearing of 27.8% at year-end. These figures show improving cash generation alongside an ongoing statutory loss, making the distinction between operating results, property valuations and financing costs important.

Retirement village turnover can be affected by residential property transactions, while care utilisation depends on resident demand and staffing capacity. Ryman Healthcare (ASX:RYM) described housing market conditions as soft in its October trading update, despite continued demand for assisted living and aged care. Revenue and cash outcomes will also depend on the pace at which contracted units settle.

Risks to Consider

Ryman faces risks from slow housing transactions, delays in converting contracts into settled sales, construction delivery and expenditure, care staffing requirements, and regulatory standards in two jurisdictions. Its financial results also reflect changes in property values, interest costs and resident-related liabilities. These exposures can create differences between accounting profit and cash performance.

What to Watch Next

Ryman Healthcare (ASX:RYM) has scheduled its 1H27 results for 25 November 2026, covering the six months ended 30 September. Key disclosures will include cash generation, occupancy, sales conversion, the progress of inventory reductions and implementation of its pricing products. The group is targeting a NZD 150 million sustainable improvement in cash flow from existing operations by FY29, with NZD 47 million reported in FY26.

Key Insights

The latest quarter recorded higher resales and increased overall care occupancy, while FY26 results showed higher operating revenue, improved EBITDAF and positive free cash flow. Ryman Healthcare (ASX:RYM) continues to manage inventory, delivery schedules and operating costs. Its November interim results will provide a fuller assessment of whether the reported sales and occupancy trends translate into financial outcomes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.